BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23263830)

  • 21. CD151 expression can predict cancer progression in clear cell renal cell carcinoma.
    Yoo SH; Lee K; Chae JY; Moon KC
    Histopathology; 2011 Jan; 58(2):191-7. PubMed ID: 21323946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High expression of Mucin13 associates with grimmer postoperative prognosis of patients with non-metastatic clear-cell renal cell carcinoma.
    Xu Z; Liu Y; Yang Y; Wang J; Zhang G; Liu Z; Fu H; Wang Z; Liu H; Xu J
    Oncotarget; 2017 Jan; 8(5):7548-7558. PubMed ID: 27911274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low NR3C2 levels correlate with aggressive features and poor prognosis in non-distant metastatic clear-cell renal cell carcinoma.
    Zhao Z; Zhang M; Duan X; Deng T; Qiu H; Zeng G
    J Cell Physiol; 2018 Oct; 233(10):6825-6838. PubMed ID: 29693713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interleukin-11 receptor predicts post-operative clinical outcome in patients with early-stage clear-cell renal cell carcinoma.
    Pan D; Xu L; Liu H; Zhang W; Zhu Y; Xu J; Gu J
    Jpn J Clin Oncol; 2015 Feb; 45(2):202-9. PubMed ID: 25420690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Homeodomain interacting protein kinase-2 phosphorylates FOXM1 and promotes FOXM1-mediated tumor growth in renal cell carcinoma.
    Liu F; Li N; Liu Y; Zhang J; Zhang J; Wang Z
    J Cell Biochem; 2019 Jun; 120(6):10391-10401. PubMed ID: 30609136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance.
    Zhao F; Siu MK; Jiang L; Tam KF; Ngan HY; Le XF; Wong OG; Wong ES; Gomes AR; Bella L; Khongkow P; Lam EW; Cheung AN
    PLoS One; 2014; 9(11):e113478. PubMed ID: 25411964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TMSB10 acts as a biomarker and promotes progression of clear cell renal cell carcinoma.
    Pan Q; Cheng G; Liu Y; Xu T; Zhang H; Li B
    Int J Oncol; 2020 May; 56(5):1101-1114. PubMed ID: 32319572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The expression of Eg5 predicts a poor outcome for patients with renal cell carcinoma.
    Sun D; Lu J; Ding K; Bi D; Niu Z; Cao Q; Zhang J; Ding S
    Med Oncol; 2013 Mar; 30(1):476. PubMed ID: 23371254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of immunohistochemical staining for myoferlin in clear cell renal cell carcinoma and its association with epidermal growth factor receptor expression.
    Jung M; Lee C; Park JH; Moon KC
    Urol Oncol; 2019 Nov; 37(11):812.e9-812.e16. PubMed ID: 31421995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FOXM1 is required for small cell lung cancer tumorigenesis and associated with poor clinical prognosis.
    Liang SK; Hsu CC; Song HL; Huang YC; Kuo CW; Yao X; Li CC; Yang HC; Hung YL; Chao SY; Wu SC; Tsai FR; Chen JK; Liao WN; Cheng SC; Tsou TC; Wang IC
    Oncogene; 2021 Jul; 40(30):4847-4858. PubMed ID: 34155349
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integration of NRP1, RGS5, and FOXM1 expression, and tumour necrosis, as a postoperative prognostic classifier based on molecular subtypes of clear cell renal cell carcinoma.
    Yoshida T; Ohe C; Ikeda J; Atsumi N; Saito R; Taniguchi H; Ohsugi H; Sugi M; Tsuta K; Matsuda T; Kinoshita H
    J Pathol Clin Res; 2021 Nov; 7(6):590-603. PubMed ID: 34212534
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased expression of ALDH1A1 protein is associated with poor prognosis in clear cell renal cell carcinoma.
    Wang K; Chen X; Zhan Y; Jiang W; Liu X; Wang X; Wu B
    Med Oncol; 2013; 30(2):574. PubMed ID: 23585015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Downregulation of FOXO3a promotes tumor metastasis and is associated with metastasis-free survival of patients with clear cell renal cell carcinoma.
    Ni D; Ma X; Li HZ; Gao Y; Li XT; Zhang Y; Ai Q; Zhang P; Song EL; Huang QB; Fan Y; Zhang X
    Clin Cancer Res; 2014 Apr; 20(7):1779-90. PubMed ID: 24486593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alpha-enolase is a potential prognostic marker in clear cell renal cell carcinoma.
    White-Al Habeeb NM; Di Meo A; Scorilas A; Rotondo F; Masui O; Seivwright A; Gabril M; Girgis AH; Jewett MA; Yousef GM
    Clin Exp Metastasis; 2015 Aug; 32(6):531-41. PubMed ID: 26037892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Down-regulation of human leukocyte antigen class I (HLA-I) is associated with poor prognosis in patients with clear cell renal cell carcinoma.
    Yuan J; Liu S; Yu Q; Lin Y; Bi Y; Wang Y; An R
    Acta Histochem; 2013 Jun; 115(5):470-4. PubMed ID: 23245688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decreased Expression of SETD2 Predicts Unfavorable Prognosis in Patients With Nonmetastatic Clear-Cell Renal Cell Carcinoma.
    Liu W; Fu Q; An H; Chang Y; Zhang W; Zhu Y; Xu L; Xu J
    Medicine (Baltimore); 2015 Nov; 94(45):e2004. PubMed ID: 26559293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overexpression of FOXM1 is associated with poor prognosis and clinicopathologic stage of pancreatic ductal adenocarcinoma.
    Xia JT; Wang H; Liang LJ; Peng BG; Wu ZF; Chen LZ; Xue L; Li Z; Li W
    Pancreas; 2012 May; 41(4):629-35. PubMed ID: 22249132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. S100A8 Expression May Have a Prognostic Value in CCRCC Reflecting TNM Staging and Fuhrman Nuclear Grade.
    An HJ; Koh HM; Song DH
    Anticancer Res; 2019 Sep; 39(9):4681-4685. PubMed ID: 31519567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High expression of interleukin-11 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma.
    Pan D; Xu L; Liu H; Zhang W; Liu W; Liu Y; Fu Q; Xu J
    Cancer Sci; 2015 May; 106(5):592-7. PubMed ID: 25702890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Involvement of FoxM1 in non-small cell lung cancer recurrence.
    Xu N; Wu SD; Wang H; Wang Q; Bai CX
    Asian Pac J Cancer Prev; 2012; 13(9):4739-43. PubMed ID: 23167412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.